NOTE: This article was updated Sept. 14 to include quotes from Acelyrin executive Tyler Marciniak. Biotechnology companies aren’t raising as much money in 2022 as they did in 2021, but Acelyrin is defying that trend, with a $300 million Series C raise announced Sept. 13. The Los Angeles-based startup's new raise comes just 10 months…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
